共 157 条
- [1] Vaduganathan M(2022)SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials Lancet 400 757-767
- [2] Docherty KF(2022)2022 aha/acc/hfsa guideline for the management of heart failure: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines J Am Coll Cardiol 79 e263-e421
- [3] Claggett BL(2022)Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the deliver randomized clinical trial JAMA Cardiol. 7 1259-1263
- [4] Jhund PS(2021)In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction J Am Coll Cardiol 78 2004-2012
- [5] de Boer RA(2021)Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-systematic review and meta-analysis of randomized placebo-controlled trials Am Heart J 232 10-22
- [6] Hernandez AF(2020)Efficacy and safety of sglt2 inhibitors in heart failure: systematic review and meta-analysis ESC Heart Fail. 7 3298-3309
- [7] Inzucchi SE(2022)Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the deliver trial Circulation 146 1210-1224
- [8] Kosiborod MN(2022)Cost-effectiveness of empagliflozin in patients with heart failure with preserved ejection fraction JAMA Intern Med 182 1278-1288
- [9] Lam CSP(2023)Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction JAMA Cardiol. 8 419-428
- [10] Martinez F(2022)Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction J Am Coll Cardiol. 80 1302-1310